Reuters logo
BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
2017年11月7日 / 下午1点49分 / 10 天前

BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma

Nov 7 (Reuters) - Cellectar Biosciences Inc:

* Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below